MA27542A1 - Compositions a delitement intra-oral, acceptables du point de vue organoleptique. - Google Patents

Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Info

Publication number
MA27542A1
MA27542A1 MA27587A MA27587A MA27542A1 MA 27542 A1 MA27542 A1 MA 27542A1 MA 27587 A MA27587 A MA 27587A MA 27587 A MA27587 A MA 27587A MA 27542 A1 MA27542 A1 MA 27542A1
Authority
MA
Morocco
Prior art keywords
compositions
acceptable
intra
view
oral delivery
Prior art date
Application number
MA27587A
Other languages
English (en)
Inventor
Blake C Ludwig
Uday J Shah
Trang T Le
Joseph P Reo
Ken Yamamoto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MA27542A1 publication Critical patent/MA27542A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions à délitement intra-oral, acceptables du point de vue organoleptique Des comprimés à délitement oral, fondant rapidement, et des procédés pour la préparation de ces formes posologiques sont proposés. Les compositions sont utiles dans le traitement ou la prophylaxie d'une large gamme de troubles et d'affections.
MA27587A 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique. MA27542A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
MA27542A1 true MA27542A1 (fr) 2005-10-03

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
MA27586A MA27682A1 (fr) 2001-09-26 2004-03-24 Compositions de valdecoxib a delitement intra-oral
MA27587A MA27542A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA27586A MA27682A1 (fr) 2001-09-26 2004-03-24 Compositions de valdecoxib a delitement intra-oral

Country Status (25)

Country Link
US (1) US20030181501A1 (fr)
EP (2) EP1429736A2 (fr)
JP (2) JP2005512964A (fr)
KR (2) KR20040058189A (fr)
CN (2) CN1633281A (fr)
AP (2) AP2004002999A0 (fr)
AR (1) AR037239A1 (fr)
BR (2) BR0212778A (fr)
CA (2) CA2461630A1 (fr)
CO (2) CO5570684A2 (fr)
EA (2) EA200400352A1 (fr)
EC (1) ECSP045029A (fr)
GE (1) GEP20063856B (fr)
HK (1) HK1079988A1 (fr)
IL (2) IL160855A0 (fr)
IS (2) IS7177A (fr)
MA (2) MA27682A1 (fr)
MX (2) MXPA04002798A (fr)
NO (2) NO20041258L (fr)
OA (2) OA12707A (fr)
PL (2) PL369298A1 (fr)
TN (2) TNSN04045A1 (fr)
WO (2) WO2003026697A2 (fr)
YU (1) YU34804A (fr)
ZA (2) ZA200401953B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (fr) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Compositions pharmaceutiques comprenant un ether et un inhibiteur selectif de la cyclooxygenase-2 et leur utilisations
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
WO2006070845A1 (fr) * 2004-12-28 2006-07-06 Eisai R & D Management Co., Ltd. Comprime a desintegration rapide et son procede de fabrication
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1964549A1 (fr) * 2005-12-20 2008-09-03 Eisai R&D Management Co., Ltd. Comprime se desintegrant oralement comprenant une substance liposoluble
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2007087188A2 (fr) * 2006-01-20 2007-08-02 Merck & Co., Inc. Comprimes et granules au gout masque
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CA2687124A1 (fr) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Formulations de doxepine a faible dose, incluant des formulations buccales, sublinguales et a dissolution rapide, et leurs utilisations pour traiter l'insomnie
EP2164460B1 (fr) * 2007-06-06 2017-08-09 Basf Se Préparation pharmaceutique pour produire des comprimés à délitement rapide
CN102046147B (zh) * 2007-06-06 2013-03-20 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
MX2009013063A (es) * 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
JP2010529073A (ja) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
EP2604257B1 (fr) * 2007-08-07 2017-06-28 Acelrx Pharmaceuticals, Inc. Formes posologiques transmucosales orales comprenant du sufentanil et du triazolam
WO2009118589A2 (fr) 2008-03-24 2009-10-01 Wockhardt Research Centre Compositions orodispersibles de rhéine ou de diacéréine
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
CN102988318A (zh) * 2008-11-25 2013-03-27 田边三菱制药株式会社 口腔速崩片及其制备方法
WO2010144865A2 (fr) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Procédés de traitement de troubles gastro-intestinaux
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CA2178686A1 (fr) * 1995-06-13 1996-12-14 Leslie G. Humber Formulations orales de s(+)-etodolac
JPH11513641A (ja) * 1995-10-20 1999-11-24 ファルマシア・アンド・アップジョン・カンパニー ブリスターパッケージ
BR9709097A (pt) * 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
EP0863134A1 (fr) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
DK1309315T3 (da) * 2000-08-18 2006-10-09 Pharmacia Corp Hurtigt disintegrerende oral valdecoxib-formulering

Also Published As

Publication number Publication date
HK1079988A1 (zh) 2006-04-21
AR037239A1 (es) 2004-11-03
OA12707A (en) 2006-06-26
BR0212861A (pt) 2004-10-05
KR20040044990A (ko) 2004-05-31
MXPA04002798A (es) 2004-07-05
CA2461630A1 (fr) 2003-04-03
EP1429736A2 (fr) 2004-06-23
EA200400352A1 (ru) 2004-12-30
EA200400357A1 (ru) 2004-08-26
US20030181501A1 (en) 2003-09-25
CO5570684A2 (es) 2005-10-31
EP1490035A1 (fr) 2004-12-29
WO2003026623A1 (fr) 2003-04-03
AP2004002999A0 (en) 2004-03-31
NO20041532L (no) 2004-04-15
MXPA04002652A (es) 2004-06-07
JP2005506987A (ja) 2005-03-10
OA13060A (en) 2006-11-10
WO2003026697A2 (fr) 2003-04-03
CN1703203A (zh) 2005-11-30
IS7177A (is) 2004-03-11
PL369298A1 (en) 2005-04-18
NO20041258L (no) 2003-03-27
GEP20063856B (en) 2006-06-26
JP2005512964A (ja) 2005-05-12
IL160848A0 (en) 2004-08-31
CA2461044A1 (fr) 2003-04-03
AP2004002998A0 (en) 2004-03-31
ECSP045029A (es) 2004-04-28
WO2003026623A8 (fr) 2004-09-30
IL160855A0 (en) 2004-08-31
TNSN04047A1 (fr) 2006-06-01
KR20040058189A (ko) 2004-07-03
BR0212778A (pt) 2004-12-07
PL369297A1 (en) 2005-04-18
TNSN04045A1 (fr) 2006-06-01
WO2003026697A3 (fr) 2003-07-03
CO5570659A2 (es) 2005-10-31
ZA200401953B (en) 2005-05-09
MA27682A1 (fr) 2006-01-02
ZA200402364B (en) 2005-01-13
YU34804A (sh) 2006-08-17
IS7178A (is) 2004-03-11
CN1633281A (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
MA27542A1 (fr) Compositions a delitement intra-oral, acceptables du point de vue organoleptique.
TR200002207T1 (tr) Slekoksib bileşikleri.
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
IL116083A0 (en) Liquid pharmaceutical compositions containing ondansetron and their use
CA2427227A1 (fr) Compose de lactam
WO2003106381A3 (fr) Inhibiteurs humains d'adam 10
WO2002055062A3 (fr) Comprime pharmaceutique comprenant du mesylate de paroxetine
MA27543A1 (fr) Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation.
Gurumoorthy et al. Multiple acute periodontal abscesses due to clenching
MXPA04004900A (es) Uso de propionil-l-carnitina o una de sus sales farmacologicamente aceptables para la preparacion de un medicamento para el tratamiento de la enfermedad de la peyronie.
CA2205600A1 (fr) Compositions d'ondansetron lyophilisees